燃石医学上涨5.23%，报19.72美元/股，总市值2.12亿美元

Core Insights - The stock of Burning Rock Medical (BNR) increased by 5.23% on December 17, reaching $19.72 per share, with a total market capitalization of $212 million [1] - As of September 30, 2025, the company's total revenue was 413 million RMB, reflecting a year-on-year growth of 6.02%, while the net profit attributable to the parent company was -39.96 million RMB, showing a significant year-on-year increase of 84.94% [1] Company Overview - Burning Rock Medical was established in 2014 with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and R&D directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) multi-cancer early detection [1] Regulatory Milestones - In July 2018, Burning Rock Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [1] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [1] Future Directions - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [1]